# Fosamprenavir Expanded Access

> **NCT00240552** · PHASE4 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 85 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** fosamprenavir
- **DRUG:** Telzir®

## Key facts

- **NCT ID:** NCT00240552
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2016-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240552, "Fosamprenavir Expanded Access". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00240552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*